Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate
about
Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsCannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activationChemotherapy-and cancer-related nausea and vomitingTreatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and VomitingRegulation of nausea and vomiting by cannabinoids and the endocannabinoid systemToxicities of the platinum antineoplastic agents.Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experienceCheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.Antiemetics: American Society of Clinical Oncology clinical practice guideline update.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.Insight in the prediction of chemotherapy-induced nausea.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.How do patient expectancies, quality of life, and postchemotherapy nausea interrelate?Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy.5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.An exploratory study on the effects of an expectancy manipulation on chemotherapy-related nausea.Treatment of Chemotherapy-Induced Nausea in Cancer Patients.Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors.The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting.Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomitingAprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparisonGinger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.Emerging drugs for chemotherapy-induced emesis.Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysisPalonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer.Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.Hypnosis for cancer care: over 200 years young.The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew)The utility of screening in the design of trials for symptom management in cancer.Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)Treatment of Nausea and Vomiting During Chemotherapy.Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.Chemotherapy-induced complications in patients with lung cancer: An evaluation by pharmacists.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
P2860
Q24243745-69DD474F-318E-4087-B3C8-6AF84AB48E64Q24605572-C48D94F6-9E60-4981-88EF-C0D96586D10DQ24644831-20CBC655-159F-4D7C-8823-03484A864299Q26784070-299FE704-9A54-4614-AA71-ECC649983C07Q28301264-C8828F47-9B69-4F3D-8062-D0F4F6972FE4Q33357351-C0ED5B05-265D-4756-BA64-0B6595FAD7DCQ33584510-1DA757FF-0C2A-4BE7-8567-0B42698DEB8AQ33866119-7B2C2317-3E04-4DF4-9795-0DD741662D8DQ34013540-9224F2BF-0355-4FBA-955C-FD772260A17FQ34030613-22593224-8FF6-4707-A45D-96B037A54629Q34418467-46E3ECDF-AEE7-4522-B1AD-E6604AA1B322Q34472901-8EBFE42B-1C74-4BCC-91E8-2E4CD72008F3Q34635638-62151893-E5D3-4D8F-AF77-142AE1C3BDBBQ34647257-F02925EF-C6F5-4607-ABAE-69456EA9EA95Q34815338-B7585DD6-39A8-4CD5-BD06-5985F166EF24Q35056522-D62B28BC-DCCD-46AC-8F45-1585B2B2A7C7Q35146420-DD5EA82D-1DA3-4DE9-849D-AD51CA68174FQ35165926-6DD81BC6-EDF3-4DA0-8B15-9365A9BF3684Q35282520-7CE7B42D-815E-4F70-8C8A-837D324F83FDQ35627742-DF707F02-A584-40B9-BB4E-A8F2A1C7F32DQ35766352-9995DE36-CDBB-45EE-B6F5-461045038159Q35870991-EF1CC3D9-AFA4-4450-B7ED-F8EA386456DFQ35918427-6BC2ADEA-E3F2-4BBD-9F64-340FB73DB0FFQ35962019-A8B89EED-CF88-4593-8286-6B9C62EC0218Q35970506-F6C53BD3-0B5C-445A-A084-B0E4E55DF304Q35991959-FA5574DA-065E-45A0-A8EF-48669E61A780Q36371595-1F28DF17-EEB6-49F5-AEB8-43A68B83F70FQ36407422-F598D045-20C3-43A3-B0FF-E89E34BC57C0Q36524349-B9D92FD4-089A-4024-8D2D-0EE19FA8E53FQ36616499-77A5999C-5FE2-402D-B1E1-97F66F391AAEQ36764063-1B24727E-2AFC-43C8-BE0C-61258208E18DQ36990036-E97F65AF-AD9A-43D1-BAFF-092E98D7C56AQ37127312-9334C39F-0E06-4050-80EA-21223BE098BAQ37193771-01FE4D4B-11A4-4B8F-83A7-64469AF5F95CQ37386449-296B322C-488D-4650-B291-E681304BD7F2Q37471168-23A1E5C9-8FBF-40EB-B7C4-D5FBC936C8F0Q37503489-A2ABF1CA-9DC6-4037-AE8A-49190A6C15ECQ37636028-FD0DB8E7-7112-4C3E-92E6-17687D68285FQ37641073-2C640356-2142-4A87-A23C-2A87F30EBD69Q37771953-A7C4B4E3-7A76-49C2-A29B-6657BC1B5B12
P2860
Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Nausea and emesis remain signi ...... of 360 cancer patients treate
@en
Nausea and emesis remain signi ...... of 360 cancer patients treate
@nl
type
label
Nausea and emesis remain signi ...... of 360 cancer patients treate
@en
Nausea and emesis remain signi ...... of 360 cancer patients treate
@nl
prefLabel
Nausea and emesis remain signi ...... of 360 cancer patients treate
@en
Nausea and emesis remain signi ...... of 360 cancer patients treate
@nl
P2093
P356
P1433
P1476
Nausea and emesis remain signi ...... of 360 cancer patients treate
@en
P2093
David K King
Gary R Morrow
James N Atkins
Jane T Hickok
Joseph A Roscoe
Tom R Fitch
P304
P356
10.1002/CNCR.11408
P407
P577
2003-06-01T00:00:00Z